Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor

  • Kalle E. Mattila (Creator)
  • Siru Mäkelä (Helsinki University Central Hospital) (Creator)
  • Soili Kytölä (Creator)
  • Emma Andersson (Creator)
  • Pia P. Vihinen (Creator)
  • Susan Ramadan (Creator)
  • Tanja Skyttä (Creator)
  • Leena Tiainen (Creator)
  • Meri-Sisko Vuoristo (Creator)
  • Kristiina Tyynelä-Korhonen (Creator)
  • Jussi Koivunen (Medical Research Center Oulu) (Creator)
  • Laura Kohtamäki (Helsinki University Central Hospital) (Creator)
  • Kristiina Aittomäki (Creator)
  • Micaela Hernberg (Creator)

    Tietoaineisto

    Kuvaus

    Detectable circulating tumor DNA (ctDNA) has been associated with worse prognosis in melanoma patients. We studied plasma ctDNA as a prognostic biomarker in 19 patients with metastatic melanoma and a detectable tumor mutation (13 BRAF, 5 NRAS, and 1 KRAS). Patients had received chemotherapy, interferon-alpha, and vemurafenib in a prospective clinical trial. Mutant allele frequency (MAF %) was determined with droplet digital PCR from pretreatment and sequential plasma samples. Higher pretreatment plasma ctDNA levels (MAF ≥3%) and detectable plasma ctDNA levels (MAF >0%) at the time of radiologically confirmed best objective response were associated with poor prognosis even when accounting for other relevant prognostic factors including performance status, tumor mutation, metastasis stage, and lactate dehydrogenase levels in multivariable analysis. Higher pretreatment plasma ctDNA levels and sustained detectable plasma ctDNA levels during treatment indicated poor prognosis in metastatic melanoma patients.
    Koska saatavilla2022

    Field of science, Statistics Finland

    • 3122 Syöpätaudit

    Siteeraa tätä